Eloralintide has no approved dose, because it is approved nowhere as of October 2, 2026. Its published trials gave it once a week by injection under the skin, at weekly doses from 1 to 9 mg in phase 2 and single doses from 0.04 to 12 mg in the first trial in people.
How the dose was reached mattered as much as the dose itself: in phase 2, nausea affected 64% of people started on 6 mg but 25% of those who climbed from 3 mg to 9 mg. The five phase 3 trials test four doses that the registry does not name.
Phase 2: weekly doses for 48 weeks
The phase 2 trial in 263 adults with obesity or overweight and no diabetes tested four fixed doses and two escalation schemes against placebo:
| Trial and group | Dose | Frequency | Duration | Route |
|---|---|---|---|---|
| Phase 2, fixed dose Human studyPMID 41207310 | 1, 3, 6 or 9 mg from the first injection | Once weekly | 48 weeks | Subcutaneous |
| Phase 2, 6 to 9 mg escalation Human studyPMID 41207310; NCT06230523 | 6 mg for 20 weeks, then 9 mg | Once weekly | 48 weeks | Subcutaneous |
| Phase 2, 3 to 9 mg escalation Human studyPMID 41207310; NCT06230523 | 3 mg for 4 weeks, 6 mg for 4 weeks, then 9 mg | Once weekly | 48 weeks | Subcutaneous |
Weight change at 48 weeks under the efficacy estimand ran from 9.4% on 1 mg to 20.1% on 9 mg, against 0.4% on placebo. The two escalation schemes ended at 9 mg: the one that started at 6 mg reached 19.9%, and the one that started at 3 mg reached 16.5%. In this trial the slower start came with a few points less weight loss and about half the rate of nausea.
Phase 1: the first doses in people
| Trial and group | Dose | Frequency | Duration | Route |
|---|---|---|---|---|
| Phase 1, single ascending dose (healthy volunteers) Human studyPMID 41109426 | 0.04 to 12 mg, once | Single dose | 4 weeks of follow-up | Subcutaneous |
| Phase 1, multiple ascending dose Human studyPMID 41559929 | Five dose cohorts started at the full dose (the abstract names a 6 mg cohort) | Once weekly | 12 weeks | Subcutaneous |
The single-dose study gave 48 healthy volunteers one injection each and followed them for four weeks; a single 12 mg dose lowered weight by 4.4% at week four, against a 0.6% gain on placebo. The 12-week multiple-dose study started each cohort at its full dose, without escalation, and reported mean weight loss of 2.6% to 11.3% across the dose groups.
EloraTZP: doses with tirzepatide
The EloraTZP phase 2b trial in 367 adults with type 2 diabetes combined eloralintide with tirzepatide, given as separate injections. Tirzepatide started at 2.5 mg and went up every four weeks to its target dose:
| Trial and group | Dose | Frequency | Duration | Route |
|---|---|---|---|---|
| EloraTZP phase 2b, combinations Human studyEli Lilly, September 30, 2026 (not yet published) | Eloralintide 3, 6 or 9 mg with tirzepatide 5, 10 or 15 mg | Once weekly | 48 weeks | Subcutaneous |
| EloraTZP phase 2b, eloralintide alone Human studyEli Lilly, September 30, 2026 (not yet published) | 3, 6 or 9 mg, started at 1 or 3 mg | Once weekly | 48 weeks | Subcutaneous |
| EloraTZP phase 2b, add-on group Human studyEli Lilly, September 30, 2026 (not yet published) | Eloralintide from week 24: 3 mg, then 6 mg after 4 weeks, on top of tirzepatide | Once weekly | 48 weeks | Subcutaneous |
The tested combinations were eloralintide 3 mg with tirzepatide 5 mg, 6 mg with 5 mg, 6 mg with 10 mg, and 9 mg with 15 mg. These figures come from Lilly's announcement and have not yet been published in a journal.
Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
Phase 3: four doses, not yet named
ENLIGHTEN-1, ENLIGHTEN-2 and ENLIGHTEN-6 each compare four eloralintide doses with placebo, and ENLIGHTEN-3 and -4 compare eloralintide with placebo in two sub-studies each. ClinicalTrials.gov lists the doses only as "Dose 1" to "Dose 4", so the doses Lilly expects to take forward have not been disclosed as of October 2, 2026. Each trial measures weight at 64 weeks.
Why escalation matters
Amylin drugs, like GLP-1 drugs, mostly cause gastrointestinal side effects at the start of treatment and after each step up. In eloralintide's phase 2 trial, starting at 6 mg gave nausea in 64% of people and vomiting in 7 of 28; climbing from 3 mg to 9 mg over eight weeks gave nausea in 25% and vomiting in 1 of 52. Lilly says its EloraTZP phase 3 will use an optimised escalation schedule. None of this tells anyone what dose to take: it describes how trial schedules were chosen.
Frequently asked questions
What dose of eloralintide was used in trials?
The phase 2 trial used weekly doses of 1, 3, 6 and 9 mg, and two schemes that climbed to 9 mg. The first trial in people gave single doses from 0.04 to 12 mg. None of these is a recommended dose.
Is there a recommended dose of eloralintide?
No. Eloralintide is approved nowhere as of October 2, 2026, so no regulator has set a dose, and its trial doses are not guidance.
What dose will be approved?
Nobody knows yet. The phase 3 trials test four doses that ClinicalTrials.gov does not name, and any approved dose would come from their results.
Why did the trials raise the dose slowly?
Starting low and stepping up reduced nausea. In phase 2, 64% of people started on 6 mg had nausea, against 25% of those who climbed from 3 mg.
Related on Grey Peptides
Sources
- Billings LK, et al. "Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial." Lancet. 2025;406(10520):2631-2643.
- Briere DA, et al. "Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept." Mol Metab. 2025;102:102271.
- Bhattachar S, et al. "Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept." Diabetes Obes Metab. 2026;28(4):2651-2660.
- Eli Lilly and Company. EloraTZP (combination of eloralintide and tirzepatide) phase 2b results. News release, September 30, 2026. Read October 2, 2026.
- ClinicalTrials.gov: NCT06230523 (escalation schedules) and the ENLIGHTEN records NCT07321886, NCT07282600, NCT07369011, NCT07353931 and NCT07392190 (doses listed as Dose 1 to Dose 4). Read October 2, 2026.
Medical disclaimer: This page is for education only and is not medical advice. EloraTZP and eloralintide are investigational and not approved for use. Do not start, stop, or self-administer any drug based on this page; consult a licensed clinician.